Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04336969
Other study ID # 52812
Secondary ID 1R18DK122422-01A
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date June 18, 2020
Est. completion date December 30, 2025

Study information

Verified date January 2024
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The 4Ts program encompasses: Teamwork, Targets, Technology, and Tight Control. These methods will help patients better manage their condition of Type 1 Diabetes with improved patient reported outcomes.


Description:

The goal of the 4T study is to implement proven methods and emerging diabetes technology into investigator's clinical practice to sustain tight glucose control from the onset of type 1 diabetes (T1D) and optimize patient reported and psychosocial outcomes. The investigators will define a program (4T - Teamwork, Targets, Technology, and Tight Control) translatable to Pediatric Diabetes clinics in the United States that reduces HbA1c and T1D burden and improves patient well-being. Study Design: This is a prospective, open-label, pragmatic research study. Two related studies will be performed. In Study 2, a cohort of new onsets (160+) receiving the 4T new onset intervention designed to decrease the rise in HbA1c seen from 4 to 12 months but following a tapered remote monitoring schedule will be compared to internal (4T Pilot and 4T Study 1) and external contemporaneous controls (CMH and DPV).


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 500
Est. completion date December 30, 2025
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 6 Months to 21 Years
Eligibility Inclusion Criteria: (Inclusion criteria includes all youth with new onset T1D seen in the Stanford/Lucile Packard Children's Hospital ages 6 months-21 years of age. We intend to include all possible patients with the goal of maximizing generalizability of the results and 4T program. (NOTE: We will include children and families who speak all languages using the Stanford interpreter services so as to have the greatest generalizability of the research. Questionnaires will only be given to English and Spanish speakers.) - All individuals within one month of T1D diagnosis seen at the Stanford Children's Diabetes Clinic - Individuals who plan to receive follow up care at the Stanford Children's Diabetes Clinic - Individuals who agree to CGM data integration into the EMR for remote monitoring - Age: six months to < 21 years of age - Patient or guardian must own and operate an Apple compatible device (e.g., iPhone or iPod Touch) to allow for Dexcom app and Apple HealthKit integration and transmission to the hospital server-based remote monitoring system and EHR. Dr Prahalad's LPCH Auxiliary Fund grant (in addition to the R18) has resources to support iPod Touch purchase for participants who do not have these. o For the Exercise Ancillary study: 11 to < 21 years of age (the activity tracker is not validated for younger children) English and Spanish-Speaking (Study 2) Exclusion Criteria: - Diabetes diagnosis other than T1D - Diagnosis of diabetes > one month prior to initial visit - Individuals with the intention of obtaining diabetes care at another clinic - Individuals who do not consent to CGM use, CGM data integration, remote monitoring - Individuals > 21 years of age

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
4T Education and Care
CGM data will be used to create customized weekly feedback to the participant/family by secure MyChart message.

Locations

Country Name City State
United States Franziska Katherine Bishop Steamboat Springs Colorado

Sponsors (3)

Lead Sponsor Collaborator
Stanford University National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other T1D Patients receiving 4T education and care monitored on a step-down cadence in study 2, will achieve an HBA1c non-inferior to weekly review Newly diagnosed T1D patients receiving 4T education and care monitored on a step-down cadence will H1a) achieve a 4-12 month change in HbA1c noninferior to that achieved under weekly review by a margin of 0.1 among 4T Pilot and 4T Study 1 patients and H1b) achieve a lower 4-12 month trajectory relative to external contemporary controls. 4-12 month trajectory in study 2
Primary Change in rise of HbA1c Rise in HbA1c (a measure of blood sugar levels over the previous 3 months) as a measurement of the effect of 4T education and care. Collected through a blood sample. Baseline, 6 months and 12 months post-diagnosis
Secondary Change in CGM Benefits and Burden Scale This tool measures the benefits and burden of Continuous Glucose Monitor (CGM) device use, and is reported by participants.
PERCEIVED BENEFITS OF CGM SCALE (BenCGM):
Below is a list of things people might think are good about wearing a CGM.
5 - Strongly agree 4 -Agree 3 - Neutral 2 - Disagree
1 - Strongly disagree
Baseline, 3, 6, 9 and 12 months
Secondary Change Diabetes Distress Scale This measure is widely used to capture the psychological distress experienced in relation to diabetes, and is reported by participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher distress, a worse outcome
Not a Problem
A Slight Problem
A Moderate Problem
Somewhat Serious Problem
A Serious Problem
A Very Serious Problem
Baseline, 3, 6, 9 and 12 months
Secondary Change in Diabetes Technology Attitude Scale This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices, and is reported by participants.
Tool lists statement and participants reports how much they agree with the statement.
1 2 3 4 5 Strongly disagree Disagree Neutral Agree Strongly agree
Baseline, 3, 6, 9 and 12 months
Secondary Change in Parental Diabetes Distress Scale The Parental Diabetes Distress Scale (PARENT-DDS) measure is widely used to capture the psychological distress experienced by parents in relation to diabetes, and is reported by participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher distress, a worse outcome
Not a Problem
A Slight Problem
A Moderate Problem
Somewhat Serious Problem
A Serious Problem
A Very Serious Problem
Baseline, 3, 6, 9 and 12 months
Secondary Change in Promise Global Health Scale This measure is widely used to capture general and overall health, and is reported by participants.
PROMISE GLOBAL HEALTH SCALES
5, Excellent | 4, Very Good | 3, Good | 2, Fair | 1, Poor
Baseline, 3, 6, 9 and 12 months
Secondary Change in Physical Activity, Youth Physical Activity Questionnaire (Y-PAQ) Youth Physical Activity Questionnaire (Y-PAQ) is a measure used to determine overall physical activity in the last 7 days, and is reported by participants.
Score Range: 1 to 3. Interpretation: Higher scores indicate higher levels of physical activity, a better outcome.
Baseline, 3, 6 and 9 months
Secondary Change in Physical Activity, International Physical Activity Questionnaire (IPAQ) International Physical Activity Questionnaire (IPAQ) asks about physical activity and sedentary behavior in the last 7 days, and is reported by participants.
Score Range: 1 to 3. Interpretation: Higher scores indicate higher levels of physical activity, a better outcome.
Baseline, 3, 6 and 9 months
Secondary Change in participant Hypoglycemic Fear Scale People with diabetes worry about hypoglycemia. Hypoglycemic Fear Survey (HFS-II) measure captures those worries and is reported by participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher levels of stress, a worse outcome
Baseline, 3, 6 and 9 months
Secondary Change in parent Hypoglycemic Fear Scale Parents of children with diabetes worry about hypoglycemia. Hypoglycemic Fear Survey (HFS-P) measure captures those worries and is reported by parents of participants.
Score Range: 0-4 Interpretation: Higher scores indicates higher levels of stress, a worse outcome
Baseline, 3, 6 and 9 months
Secondary Change in Self-Efficacy for Exercise Scale Self-Efficacy for Exercise (SEE) Scale measures how confident people are in their ability to overcome barriers to exercise.
Total scale is calculated by summing the responses to each question. The scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise.
Baseline, 3, 6, and 9 months
Secondary Change in education exposure to safe exercise strategies Percentage of participants attending at least one telehealth session and a measure of education exposure to safe exercise strategies Baseline, 3, 6, and 9 months
See also
  Status Clinical Trial Phase
Completed NCT03886974 - Transition to Adult Care in Type 1 Diabetes
Completed NCT05620251 - Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Active, not recruiting NCT05078658 - Low-carbohydrate Diet in Children With Type 1 Diabetes N/A
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Completed NCT03177096 - Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes N/A
Not yet recruiting NCT06418269 - The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes N/A
Completed NCT04172077 - Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
Recruiting NCT04950634 - Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Completed NCT04450745 - Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients N/A
Completed NCT03165786 - A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes N/A
Terminated NCT04028960 - IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase Phase 2
Recruiting NCT05324488 - Diabetes Registry Graz for Biomarker Research
Completed NCT02984709 - Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes N/A
Completed NCT02984514 - Brown Adipose Tissue in Type 1 Diabetes N/A
Recruiting NCT06372392 - Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps N/A
Recruiting NCT03311516 - New Insulin Therapy by Multiwave Bolus N/A
Recruiting NCT05973799 - Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes N/A
Completed NCT03711656 - Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques N/A